MENOSTAR
LOE ApproachingNDATRANSDERMALSYSTEM
Approved
Jun 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
MENOSTAR by Bayer is characteristics. First approved in 2004.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MENOSTAR is a transdermal estradiol delivery system approved in 2004 for hormone replacement therapy in postmenopausal women. It delivers estradiol, the principal human estrogen, which binds to nuclear estrogen receptors to reduce elevated luteinizing hormone and follicle-stimulating hormone levels characteristic of menopause. The product addresses vasomotor symptoms and other menopausal manifestations through physiologic estrogen replacement.
$0.612MPart D
LOE ApproachingDeclining market opportunity with minimal current claims volume signals reduced team investment and competitive saturation in the menopause hormone therapy space.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Started Feb 2004
500 enrolled
Osteopenia
Worked on MENOSTAR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.